Submitted by Rachel Ainsworth on Fri, 2016-11-18 08:03
EY, commissioned by the UK Treasury, sets out to assess how the UK fintech ecosystem compares to that of other regions with a significant fintech presence.
Forensic data analytics (FDA) has evolved considerably over the past two years. In our 2014 survey, we found that, although companies were deploying some forms of FDA, many were missing opportunities to leverage emerging advanced tools that would enable them to greatly strengthen and improve their risk management and investigative response programs.
Roughly half of the companies surveyed…are considering a divestment in the next two years. Yet many of these companies will struggle to generate maximum value from their divestments. This is all the more reason to share leading practices now.
Submitted by Rachel Ainsworth on Thu, 2016-07-28 16:46
This report is founded on extensive research: one-on-one interviews with 21 CFOs and a survey of nearly 800 finance leaders. EY effectively captures the reader’s interest by highlighting this approach and naming all the interviewees on the very first page, and profiling (with large photos) a number of them throughout the report.
Submitted by Source Admin on Wed, 2015-12-23 10:06
EY continues to bounce around our table due to the high variability of its content. While we saw no outstanding content
(scoring 12 or more points under our rating criteria), we could point to examples in this sample that sit everywhere from ’a
good piece of thought leadership’ to ’this could actually be detrimental to the brand’.
Submitted by Source Admin on Thu, 2015-09-10 13:07
As we suspected might happen, EY’s score has dropped again this review. The firm produces an awful lot of material – some of which is very good, some of which is fairly poor. One of the higher-scoring pieces this time is Beyond borders, a report targeting the biotechnology industry. We accept that it is rather on the hefty side, but it’s easy to navigate, allowing readers to dip in to areas of interest.